Boston, Massachusetts, United States, October 2025 — Aatiyah Paulding, SHRM-SCP has been appointed as the Senior Director, People at Bicara Therapeutics, marking a new chapter in her distinguished career in human resources and organizational leadership. With over 15 years of experience across higher education, biotechnology, and technology-driven companies, Aatiyah brings deep expertise in people strategy, talent development, and employee engagement to her new role.
Before joining Bicara Therapeutics, Aatiyah served at Sage Therapeutics for five years, most recently as Senior Director, People & Experience (Commercial HRBP and Learning & Organizational Growth Lead). At Sage, she played a pivotal role in building a culture of inclusion and performance, spearheading leadership development programs and aligning people initiatives with the company’s commercial growth.
Prior to Sage, Aatiyah was an HR Business Partner at Enel X, where she led talent strategy and employee experience initiatives that supported the company’s transformation into a clean energy innovator. Earlier, she worked at Bullhorn, a leading SaaS company, as a Leader and Talent Business Partner, where she supported the global research and development organization, enhancing workforce planning and leadership capability across technical functions.
Aatiyah began her HR career at Harvard University, where she held several progressive roles over more than a decade, including Human Resources Consultant. Her tenure at Harvard was marked by her strategic work in organizational design, change management, and employee development, fostering an environment of growth and collaboration across multiple academic departments.
In her new role at Bicara Therapeutics, Aatiyah will lead the company’s people strategy, driving organizational culture, employee engagement, and leadership development as Bicara continues its mission to pioneer next-generation biologics for cancer treatment.
About Bicara Therapeutics
Bicara Therapeutics is a clinical-stage biotechnology company developing first-in-class dual-action biologics that integrate the precision of targeted therapy with the immune-activating power of tumor modulators. Its novel biologics are engineered to deliver immunomodulatory payloads directly to the tumor microenvironment, enhancing immune cell activation and potentially offering durable therapeutic benefits.
Through innovation and collaboration, Bicara Therapeutics aims to redefine cancer treatment by unlocking the full potential of immunotherapy to deliver lasting efficacy and improved outcomes for patients.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
